Clostridioides Difficile Infection

Researchers found that removing Clostridioides difficile from gastrointestinal pathogen panels reduced unnecessary treatment without causing delays in diagnosis.

A pre-post-quasi-experimental study conducted at Griffin Hospital in Derby, Connecticut, revealed that using disinfectant wipes treated with a novel color additive left hospital rooms 69.2% cleaner than using regular bleach wipes.

Fecal microbiota-based therapies are becoming more prevalent in the management of Clostridioides difficile infection.

Among ventilated ICU patients with suspected infection, the length of antibiotic use went down after respiratory viral panel testing was adopted, according to results published in Annals of the American Thoracic Society.

Paxlovid, an oral antiviral approved by the FDA in May 2023, did not reduce the risk for long COVID among vaccinated, nonhospitalized patients who received it within a month of their first SARS-CoV-2 infection, a study showed.

To break the cycle of recurrent Clostridioides difficile infection, physicians have shifted treatment strategies from antibiotics to fecal microbiota transplantation and live biotherapeutic products.

Clostridioides difficile infection presents a unique treatment paradox for clinicians: Antibiotics are often both its cause and its cure.

Despite the availability of fecal microbiota transplantation and FDA-approved live biotherapeutics for recurrent Clostridioides difficile infection, some patients have turned to risky “homebrew” methods to correct their gut microbiome.

A growing outbreak of Salmonella linked to cantaloupe has sickened more than 100 people and killed two, according to the CDC.

In this episode of Meeting Mic, we bring you Healio’s top headlines from ACG 2023.